Strategic Approach to Glycoprotein and Glycosylation Analysis Intertek and NIBRT Seminar

Article

Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.

Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.

To request the agenda contact us now at biopharma@intertek.com.

The presentations will be delivered by experts in their field; Ashleigh Wake Intertek’s Biotechnology Team Leader and Professor Pauline Rudd, a leading authority on protein glycosylation.

This seminar would be of interest to professionals working in protein therapeutic development and manufacturing.

Agenda:

  • Introduction to the Intertek / NIBRT strategic collaboration
  • A Strategic approach to glycoprotein analysis – Ashleigh Wake, Intertek Biotechnology Team Leader
  • A systematic approach to protein glycosylation analysis – Prof. Pauline Rudd, NIBRT

Dates:
22nd September 2011, Intertek, Manchester, UK
23rd September 2011, NIBRT, Dublin, Ireland

Register your interest here.

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Site Logo

Supporting Merck toward a new age of aseptic fill-finish processing of highly potent drugs.

May 9th 2025
Article
Site Logo

Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes

Grace & Microsize
May 9th 2025
Article

A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.